2020 | Business Wire
TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers.
2020 | Market Watch
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
2019 | Cision PR Newswire | Read Now
BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.
2019 | Physics World | Read Now
The main obstacle to BNCT has been that a nuclear reactor was required to generate the neutron beams needed for treatments. To overcome this problem, TAE Life Sciences is developing an accelerator-based neutron source. “We have created a low-energy neutron beam source that is reliable, compact and can be installed in a hospital facility,” says Bruce Bauer, CEO of TAE Life Sciences. “This changes the game on BNCT.”
2019 | PR Newswire | Read Now
Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.
